Last reviewed 2026-06-03 · How we verify

M-M-RTM II

Merck Sharp & Dohme LLC · FDA-approved active Biologic ✓ Verified Jun 2026

M-M-RTM II is a Live attenuated viral vaccine Biologic drug developed by Merck Sharp & Dohme LLC. It is currently FDA-approved for Prevention of measles, mumps, and rubella in children and adults.

M-M-R II is a live attenuated viral vaccine that stimulates immune responses against measles, mumps, and rubella by introducing weakened forms of these viruses.

M-M-RTM II is a vaccine used to prevent Varicella, Measles, Mumps, and Rubella. It is a formulation of VARIVAX, a vaccine that has been studied for safety in a clinical trial.

At a glance

Generic name	M-M-RTM II
Sponsor	Merck Sharp & Dohme LLC
Drug class	Live attenuated viral vaccine
Modality	Biologic
Therapeutic area	Immunology / Infectious Disease
Phase	FDA-approved

Mechanism of action

The vaccine contains live but weakened (attenuated) strains of measles, mumps, and rubella viruses. When administered, these attenuated viruses replicate in the body at low levels, triggering both humoral (antibody) and cell-mediated immune responses without causing disease. This generates protective immunity against all three viral infections.

Approved indications

Prevention of measles, mumps, and rubella in children and adults

Common side effects

Fever
Rash
Parotitis (mumps-like symptoms)
Arthralgia/arthritis
Thrombocytopenia
Local injection site reactions

Key clinical trials

Safety Study of a Refrigerator-stable Formulation of VARIVAX® (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

M-M-RTM II CI brief — competitive landscape report
M-M-RTM II updates RSS · CI watch RSS
Merck Sharp & Dohme LLC portfolio CI

Frequently asked questions about M-M-RTM II

What is M-M-RTM II?

M-M-RTM II is a Live attenuated viral vaccine drug developed by Merck Sharp & Dohme LLC, indicated for Prevention of measles, mumps, and rubella in children and adults.

How does M-M-RTM II work?

M-M-R II is a live attenuated viral vaccine that stimulates immune responses against measles, mumps, and rubella by introducing weakened forms of these viruses.

What is M-M-RTM II used for?

M-M-RTM II is indicated for Prevention of measles, mumps, and rubella in children and adults.

Who makes M-M-RTM II?

M-M-RTM II is developed and marketed by Merck Sharp & Dohme LLC (see full Merck Sharp & Dohme LLC pipeline at /company/merck).

What drug class is M-M-RTM II in?

M-M-RTM II belongs to the Live attenuated viral vaccine class. See all Live attenuated viral vaccine drugs at /class/live-attenuated-viral-vaccine.

What development phase is M-M-RTM II in?

M-M-RTM II is FDA-approved (marketed).

What are the side effects of M-M-RTM II?

Common side effects of M-M-RTM II include Fever, Rash, Parotitis (mumps-like symptoms), Arthralgia/arthritis, Thrombocytopenia, Local injection site reactions.

Drug class: All Live attenuated viral vaccine drugs
Manufacturer: Merck Sharp & Dohme LLC — full pipeline
Therapeutic area: All drugs in Immunology / Infectious Disease
Indication: Drugs for Prevention of measles, mumps, and rubella in children and adults

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing